We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Keytruda Wins FDA Nod for Breast Cancer Treatment
Merck’s cancer immunotherapy Keytruda (pembrolizumab) has become the first drug of its kind to be approved for early triple-negative breast cancer after a previous rejection from the FDA for the indication in March due to lack of data.